Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $144.38, for a total value of $28,876.00. Following the transaction, the executive vice president now owns 21,996 shares in the company, valued at $3,175,782.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Michael Patrick Miller also recently made the following trade(s):

  • On Monday, July 17th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals plc – stock. The shares were sold at an average price of $154.97, for a total value of $30,994.00.
  • On Thursday, June 15th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals plc – stock. The shares were sold at an average price of $150.65, for a total value of $30,130.00.

Jazz Pharmaceuticals plc – (NASDAQ JAZZ) traded up 0.53% during midday trading on Wednesday, reaching $147.40. The company had a trading volume of 449,156 shares. The firm has a market capitalization of $8.85 billion, a P/E ratio of 22.70 and a beta of 1.10. The stock’s 50 day moving average price is $153.92 and its 200-day moving average price is $147.45. Jazz Pharmaceuticals plc – has a one year low of $95.80 and a one year high of $163.75.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by $0.13. The company had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals plc – had a net margin of 25.69% and a return on equity of 22.75%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the company earned $2.67 earnings per share. On average, equities research analysts anticipate that Jazz Pharmaceuticals plc – will post $10.88 earnings per share for the current year.

WARNING: “Insider Selling: Jazz Pharmaceuticals plc – (JAZZ) EVP Sells 200 Shares of Stock” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/16/insider-selling-jazz-pharmaceuticals-plc-jazz-evp-sells-200-shares-of-stock.html.

Several equities analysts have weighed in on JAZZ shares. Leerink Swann set a $179.00 target price on Jazz Pharmaceuticals plc – and gave the company a “buy” rating in a report on Thursday, April 27th. Cantor Fitzgerald restated a “buy” rating on shares of Jazz Pharmaceuticals plc – in a report on Thursday, April 27th. Zacks Investment Research upgraded Jazz Pharmaceuticals plc – from a “hold” rating to a “buy” rating and set a $174.00 target price on the stock in a report on Monday, May 15th. Vetr upgraded Jazz Pharmaceuticals plc – from a “hold” rating to a “buy” rating and set a $151.11 target price on the stock in a report on Tuesday, June 6th. Finally, Royal Bank Of Canada set a $210.00 target price on Jazz Pharmaceuticals plc – and gave the company a “buy” rating in a report on Tuesday, June 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $182.72.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. C WorldWide Group Holding A S boosted its position in Jazz Pharmaceuticals plc – by 3.7% in the first quarter. C WorldWide Group Holding A S now owns 98,465 shares of the specialty pharmaceutical company’s stock valued at $14,290,000 after buying an additional 3,493 shares in the last quarter. Monarch Partners Asset Management LLC bought a new position in Jazz Pharmaceuticals plc – during the first quarter valued at $8,733,000. Canada Pension Plan Investment Board boosted its position in Jazz Pharmaceuticals plc – by 587.5% in the first quarter. Canada Pension Plan Investment Board now owns 82,651 shares of the specialty pharmaceutical company’s stock valued at $11,995,000 after buying an additional 70,629 shares in the last quarter. Wells Fargo & Company MN boosted its position in Jazz Pharmaceuticals plc – by 0.5% in the first quarter. Wells Fargo & Company MN now owns 503,759 shares of the specialty pharmaceutical company’s stock valued at $73,111,000 after buying an additional 2,529 shares in the last quarter. Finally, Sumitomo Mitsui Asset Management Company LTD boosted its position in Jazz Pharmaceuticals plc – by 16.8% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 4,910 shares of the specialty pharmaceutical company’s stock valued at $712,000 after buying an additional 707 shares in the last quarter. 87.22% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals plc – Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with MarketBeat.com's FREE daily email newsletter.